Navigation Links
Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
Date:1/24/2008

LAVAL, QC, Jan. 24 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS, NASDAQ: DDSS) today announced that it has entered into a licensing and distribution agreement with iNova Pharmaceuticals (Australia) Pty Limited for its once-daily tramadol product for Australia.

"Building on the launch of our once-daily tramadol product across Europe and in Canada, we continue to add strong distribution partners as we prepare for additional product launches in key markets globally throughout this year," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "Australia represents a sizable opportunity and is an important component of the global commercialization plan for our product."

Under terms of the agreement, iNova will have the exclusive right to market and sell Labopharm's once-daily tramadol product in Australia. Labopharm will supply iNova with finished packaged product and will receive revenue from product sales commensurate with those of previous licensing and distribution agreements that Labopharm has entered into for European markets. Labopharm will also receive payments upon the achievement of certain milestones.

Labopharm is awaiting regulatory and pricing approval of its once-daily tramadol formulation in Australia, which is expected in the first half of 2008, with launch to occur thereafter.

About iNova Pharmaceuticals (Australia) Pty Limited

iNova Pharmaceuticals (Australia) Pty Limited develops and markets a range of over-the-counter and prescription medicines to Australasia, Asia-Pacific, South Africa and other international markets directly and also through other pharmaceutical companies and agents. The company works in partnership with sales and marketing partners and pharmaceutical companies in other countries to make their medicines available to the broader international community. iNova was borne out of more than 50 years heritage from Riker Laboratories and 3M Pharmaceuticals following t
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
10. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
11. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...Consideredahighlyriskyandcontroversialmedicalproce...life-savingmainstreamoperationthankstotheextraordi...nDallasonNov.11.Leaderscametogetherfrommedicalcent...ylorRegionalTransplantInstitute(BRTI),oneofthepion... Itwas25yearsagothatBaylorHealthCareSystemchosetop...
(Date:11/27/2009)...27 Team Garmin-Slipstream, the eli... ethical sporting and developing the next generati...ill become Team Garmin-Transitions with the additi...team. Transitions Optical is the world,s leading m... advanced photochromic technology in the widest se...
(Date:11/27/2009)... may reduce future disease burden, researchers say... Encouraging city dwellers to walk and bicycle ins... health benefits than increased used of low-emissi... study compared the projected health effects in 20...or London, England, and Delhi, India: business-as...
(Date:11/27/2009)... announced today that Spectrum Health (Grand Rapid... orthopedic templating solution and its TraumaCad ... (PRWEB) November 27, 2009 -- Voyant Health&trad...ids, Michigan) has licensed its TraumaCad Enterpri...d Extend workflow solution, to allow its orthopedi...
(Date:11/27/2009)...e anatomy education apps from Modality and Lippinc...learning opportunities for iPhone and iPod touch ...ber 27, 2009 -- Modality, Inc. and Lippincott Wi...Kluwer Health, today announced the availability of.... Clemente’s Anatomy, Rohen’s Photogra...
Breaking Medicine News(10 mins):Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5
...NE, Idaho, June 19 NightHawk,Radiology Holdings, ...iology,solutions to radiology groups and hospitals...final results of its modified Dutch auction tender...ate of 2,240,883 shares of common stock were prope...
...une 19 As the summer months approach and men,star..., it is also,important for them to set time aside ...men suffer from common symptoms such as fatigue, s....,June is Men,s Health Month and it,s important th...
...traces roots of the problem , , THURSDAY, ...alse-positive results, the use of an oral rapid HI...partment of Health and Mental Hygiene, which opera... specimens using the OraQuick test. Then, in March...
...ones, Blackberries, e-mail, laptops allowing peopl...erfectly condensed and filtered snippets via the I...n so instantaneous and information distributed so ... well-informed and close-knit society. While this ...
...The Netherlands, June 19 Agendia BV has,announced...rters yesterday,at Amsterdam,s Science Park at Wat...emony was officiated by Dr. Rene Bernards, Chief S...Economic,Affairs for The Netherlands., "Agendia h...
..., NY-- The Damon Runyon Cancer Research Foundation... Fellowship Award Committee review. The recipient...nding postdoctoral scientists conducting basic and...ourage the nation,s most promising young investiga...
Other Medicine News:Health News:NightHawk Radiology Holdings, Inc. Announces Final Results of Tender Offer; NightHawk Purchases 2,240,883 Shares of Its Common Stock at $8.05 per Share 2Health News:False Positives in Oral HIV Test Halt Use in NYC 2Health News:Unable to focus? Welcome to our distracted society's attention deficit 2Health News:Unable to focus? Welcome to our distracted society's attention deficit 3Health News:Unable to focus? Welcome to our distracted society's attention deficit 4Health News:Agendia Expands Laboratory Capacity at New Amsterdam Headquarters to Meet Increasing Demand for Services Worldwide 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 14 top young investigators 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 14 top young investigators 3Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 14 top young investigators 4
(Date:11/25/2009)....J., Nov. 25 Pharmasset,...tical company committed to discovering, developing...fections, reported financial results for the fisca...2009 Pharmasset held $58.4 million in cash, cash e...eline Update and 2009 Highlights ,, RG7128 ,...
(Date:11/25/2009)...EACH, Fla., Nov. 25 For ..., especially the 27 million living with untreated ...appy, says audiologist Cindy Beyer. ,, Dr. Beye... one of America,s largest hearing care and hearin...g loss to stress, frustration, and social isolatio...
(Date:11/25/2009)...K, Nov. 25 Reportlinker.com announ... in its catalogue: ,, United States Dental Dev... http://www.reportlinker.com/p0158733/United-State...2015.html ,, United States Dental Devices Mark...,, This report is an essential source for in-de...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 13 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 1 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 2 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 3 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 4 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 5 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 6FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 1FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 2FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 3FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 4FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 5FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 6FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 7FDA Advisory Committee Recommends Approval of PEGINTRON 28R 29 for the Adjuvant Treatment of Stage III Malignant Melanoma 58879 8PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear Nose and Throat Market 5231 1PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear Nose and Throat Market 5231 2PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear Nose and Throat Market 5231 3
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
Medicine Products: